Breaking News, Collaborations & Alliances

Taiwan Bio, TRACT Therapeutics Partner on Organ Transplant Rejection

Leverages Taiwan Bio’s expertise in cell therapy manufacturing and TRACT Therapeutics’ immune modulating regulatory T cell therapy platform.

Taiwan Bio has entered a partnership with TRACT Therapeutics to advance a cellular therapy for the prevention of allograft rejection in solid organ transplant. The partners will launch a multi-center Phase 2 trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the U.S. and Taiwan. The partnership leverages Taiwan Bio’s expertise in cellular therapy manufacturing and TRACT Therapeutics’ immune modulating regulatory T cell therapy pla...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters